%20%20-%20%20Read-Only.jpg)
Leading-edge
Collaborations
We are working with some of the world’s leading pharmaceutical and biotechnology companies who are using our POZ Platform™ to develop novel therapeutics. Our collaborations with partners to advance LNP based drug delivery in mRNA vaccines highlights the broad potential of our technology.
How Partners Are Collaborating with Us
Small Molecules
The POZ Platform™ enables the programmed release of challenging small molecules – where for example, insolubility and high first pass metabolism are limiting factors.
POZ enables these drugs to be continuously delivered via a once weekly SC injection, potentially improving compliance and efficacy over an extended therapeutic window.
RNA Vaccines & Therapeutics
We are working with partners at the forefront of RNA drug development for infectious diseases, cancer immunotherapy, and gene therapy.
Our partners are currently advancing pre- clinical studies exploring POZ-lipid LNPs as a non-immunogenic replacement for the current PEG-LNP standard that is employed in the mRNA SARS-CoV-2 vaccines.
Antibody Drugs Conjugates
POZ is uniquely suited for tuning the pharmacokinetic and metabolic properties of an ADC for better clinical performance. This is an important area in ADC drug development, as achieving the right balance can be the difference between a safe, effective therapy and one with poor efficacy or high toxicity.
Our partners have demonstrated POZ can dramatically increase the drug antibody ratio (DAR) and believe that this will be particularly important when the antigen for the ADC has low cell surface expression (low-density targets).